Contemporary multi-institutional reports—HD IL-2 outcome
| Report | Response | Survival |
| Clark et al4 RCC (2011–2015), sequenced with targeted therapy N=352 (328 with response data) PROCLAIM registry database | CR 4%, PR 13%, SD 39%, PD 43% CR+PR+SD 53% | Median OS—NR for CR, PR, SD Median OS—PD—15.5 months PD followed by TT—med OS 29.7 months; PD no TT—med OS 8.5 months 2.5-year OS—CR 100%; PR 75%, SD 78%, PD 39% |
| McDermott et al5 RCC n=120 Multi-institution, prospective trial | ORR 25%, CR 3, PR 27 13 (11%) progression-free at 3 years | Median OS 42.8 months 80% TT after IL-2 |
| Alva et al6 mM (2005–2012)—n=170 RCC (2005–2012)—n=192 Survival current 2015 PROCLAIM registry database | mM: CR 5% PR 10% SD 22% CR+PR+SD 58% median f/u 43.1 months RCC: CR 6%, PR 9%, SD 22% CR+PR+SD 70% median f/u 46.6 months | Median OS 19.6 months Median OS—NR for CR, PR Median OS 33.4 months—SD Median OS 41 months Median OS—NR for CR, PR Median OS 49.6 months—SD |
| Stenehjem et al7 RCC n=391 U Utah 1988–2013 U Mich 1997–2013 | CR 9% PR 10%, SD 32% PD 42% CR+PR+SD 51% | Median OS CR—13+ years Median OS PR—37.8 months Median OS SD—34.4 months |
CR, complete response; f/u, follow-up; IL, interleukin; mM, metastatic melanoma; N, number; NR, not reached; ORR, overall response rate; OS, overall survival; PD, progressive disease; PR, partial response; RCC, renal cell carcinoma; SD, stable disease; TT, targeted therapy; U, university.